Development of HBsAg-binding aptamers that bind HepG2.2.15 cells via HBV surface antigen
Tóm tắt
Hepatitis B virus surface antigen (HBsAg), a specific antigen on the membrane of Hepatitis B virus (HBV)-infected cells, provides a perfect target for therapeutic drugs. The development of reagents with high affinity and specificity to the HBsAg is of great significance to the early-stage diagnosis and treatment of HBV infection. Herein, we report the selection of RNA aptamers that can specifically bind to HBsAg protein and HBsAg-positive hepatocytes. One high affinity aptamer, HBs-A22, was isolated from an initial 115 mer library of ∼1.1×1015 random-sequence RNA molecules using the SELEX procedure. The selected aptamer HBs-A22 bound specifically to hepatoma cell line HepG2.2.15 that expresses HBsAg but did not bind to HBsAg-devoid HepG2 cells. This is the first reported RNA aptamer which could bind to a HBV specific antigen. This newly isolated aptamer could be modified to deliver imaging, diagnostic, and therapeutic agents targeted at HBV-infected cells.
Tài liệu tham khảo
Bock L C, Griffin L C, Latham J A, et al. 1992. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 355(6360): 564–566.
Brody E N, Gold L. 2000. Aptamers as therapeutic and diagnostic agents. J Biotechnol, 74(1): 5–13.
Chapman J A, Beckey C. 2006. Pegaptanib: A novel approach to ocular neovascularization. Ann Pharmacother, 40(7–8): 1322–1326.
Chu C M, Liaw Y F. 1987. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology, 92: 220–225.
Chu T C, Twu K Y, Ellington A D, et al. 2006. Aptamer mediated siRNA delivery. Nucleic Acids Res, 34(10): e73.
Connell G J, Illangesekare M, Yarus M. 1993. Three small ribooligonucleotides with specific arginine sites. Biochemistry, 1; 32(21): 5497–502.
Dienstag J L. 2006. Looking to the future: new agents for chronic hepatitis B. Am J Gastroenterol, 101: S19–S25.
Ellington A D, Szostak J W. 1990. In vitro selection of RNA molecules that bind specific ligands. Nature, 30; 346(6287): 818–822.
Gish R G. 2005. Current treatment and future directions in the management of chronic hepatitis B viral infection. Clin Liver Dis, 9: 541–565.
Guan R. 2005. Treatment of chronic hepatitis B infection using interferon. Med J Malaysia, 60: 28–33.
Hicke B J, Marion C, Chang Y F, et al. 2001. Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem, 28; 276(52): 48644–48654.
Hicke B J, Stephens A W. 2000. Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest, 106(8): 923–928.
Jayasena S D. 1999. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem, 45(9): 1628–1650.
Jenison R D, Jennings S D, Walker D W, et al. 1998. Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion, Antisense Nucleic Acid Drug Dev, 8(4): 265–279.
Khaled A, Guo S, Li F, et al. 2005. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Letters, 5(9): 1797–1808.
Kojima T. 1982. Immune electron microscopic study of hepatitis B virus associated antigens in hepatocytes. Gastroenterol Jpn, 17: 559–575.
Liu C J, Liou J M, Chen D S, et al. 2005. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc, 104: 783–791.
Marcellin P, Asselah T, Boyer N. 2005. Treatment of chronic hepatitis B. J Viral Hepat, 12: 333–345.
McNamara J O 2nd, Andrechek E R, Wang Y, et al. 2006. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol, 24(8): 1005–1015.
Ng E W, Shima D T, Calias P, et al. 2006. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov, 5(2): 123–132.
Ocama P, Opio C K, Lee W M. 2005. Hepatitis B virus infection: current status. Am J Med, 118: 1413.
Onishi S, Saibara T, Ito K. 1985. Hepatitis B surface antigen specific cytotoxic T lymphocyte activity in hepatitis B virus infection. Gastroenterol Jpn, 20: 330–337.
Pagratis N C, Bell C, Chang Y F, et al. 1997. Potent 2′-amino-, and 2′-fluoro-2′-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nat Biotechnol, 15(1): 68–73.
Perrillo R P. 2005. Current treatment of chronic hepatitis B: benefits and limitations. Semin Liver Dis, 25: 20–28.
Rhodes A, Deakin A, Spaull J, et al. 2000. The generation and characterization of antagonist RNA aptamers to human oncostatin M. J Biol Chem, 275(37): 28555–28561.
Rhodes A, Smithers N, Chapman T, et al. 2001. The generation and characterisation of antagonist RNA aptamers to MCP-1. FEBS Lett, 506(2): 85–90.
Rivkin A. 2005. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin, 21: 1845–1856.
Ruckman J, Green L S, Beeson J, et al. 1998. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem, 273(32): 20556–20567.
Rusconi C P, Scardino E, Layzer J, et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature. 2002; 419(6902): 90–94.
Sasaki H, Kojima T, Matsui S, et al. 1987. Interaction of lymphocytes with hepatocytes containing hepatitis B antigen: ultrastructural demonstration of target antigen andT-cell subsets by the peroxidase antibody technique. Virchows Arch A Pathol Anat Histopathol, 411: 489–498.
Shu D, Guo P. 2003. A viral RNA that binds ATP and contains a motif similar to an ATP-binding aptamer from SELEX. J Biol Chem, 278(9): 7119–7125.
Simon K, Lingappa V R, Ganem D. 1988. Secreted hepatitis B surface antigen polypeptides are derived from a transmembrane precursor. J Cell Biol, 107: 2163–2168.
Tian Y, Adya N, Wagner S, et al. 1995. Dissecting protein:protein interactions between transcription factors with an RNA aptamer. RNA, 1(3): 317–326.
Tuerk C, Gold L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 3; 249(4968): 505–510.
Watson S R, Chang Y F, O’Connell D, et al. 2000. Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo. Antisense Nucleic Acid Drug Dev, 10(2): 63–75.
Wiegand T W, Williams P B, Dreskin S C, et al. 1996. High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. J Immunol, 157(1): 221–230.
Wright T L. 2006. Introduction to chronic hepatitis B infection. Am J Gastroenterol, 101: S1–S6.